Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-126 in Mild-to-Moderate Alzheimer's Disease
NCT00948909Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2009
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of nelonicline in Alzheimer's disease (AD), sponsored by AbbVie Inc.. Started Oct 2009; status: completed.
02
Drugs
nelonicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00948909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00948909.